These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19924650)

  • 1. Laser-induced thermal therapy and cisplatin for recurrent head and neck cancer: a case characterized by an unusually long disease-free survival.
    Joo J; Sercarz JA; Paolini AA; Castro DJ; Paiva MB
    Ear Nose Throat J; 2009 Nov; 88(11):E13-6. PubMed ID: 19924650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
    Yang WC; Chen CH; Tang JY; Wu CF; Liu YC; Sun Y; Lin SF
    Anticancer Res; 2014 Jul; 34(7):3765-73. PubMed ID: 24982400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
    Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
    Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
    Lamont JP; Nemunaitis J; Kuhn JA; Landers SA; McCarty TM
    Ann Surg Oncol; 2000 Sep; 7(8):588-92. PubMed ID: 11005557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
    Khuri FR; Nemunaitis J; Ganly I; Arseneau J; Tannock IF; Romel L; Gore M; Ironside J; MacDougall RH; Heise C; Randlev B; Gillenwater AM; Bruso P; Kaye SB; Hong WK; Kirn DH
    Nat Med; 2000 Aug; 6(8):879-85. PubMed ID: 10932224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumor cisplatin nephrotoxicity in combined laser-induced thermal therapy for cancer treatment.
    Palumbo MN; Cervantes O; Eugênio C; Hortense FTP; Ribeiro JC; Paolini AAP; Tedesco AC; Sercarz JA; Paiva MB
    Lasers Surg Med; 2017 Oct; 49(8):756-762. PubMed ID: 28598516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
    Steindorfer P; Jakse R; Germann R; Schneider G; Berger A; Mischinger HJ; Rehak P
    Strahlenther Onkol; 1987 Jul; 163(7):449-52. PubMed ID: 2441480
    [No Abstract]   [Full Text] [Related]  

  • 9. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
    Kovács AF; Mose S; Böttcher HD; Bitter K
    Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of head and neck cancer.
    Tirelli U; Franchin G; Barzan L
    Ann Oncol; 1994 Jul; 5(6):553-8. PubMed ID: 7918129
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors.
    Duvillard C; Romanet P; Cosmidis A; Beaudouin N; Chauffert B
    Ann Otol Rhinol Laryngol; 2004 Mar; 113(3 Pt 1):229-33. PubMed ID: 15053208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
    Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
    Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
    Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
    Cooper JS; Pajak TF; Forastiere AA; Jacobs J; Campbell BH; Saxman SB; Kish JA; Kim HE; Cmelak AJ; Rotman M; Machtay M; Ensley JF; Chao KS; Schultz CJ; Lee N; Fu KK;
    N Engl J Med; 2004 May; 350(19):1937-44. PubMed ID: 15128893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
    Lamont EB; Vokes EE
    Lancet Oncol; 2001 May; 2(5):261-9. PubMed ID: 11905780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
    Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
    Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
    J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
    Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
    Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.